CompletedPhase 2NCT01462630

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fox Chase Cancer Center
Principal Investigator
Margaret von Mehren
Fox Chase Cancer Center
Intervention
pazopanib hydrochloride(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
20112021

Study locations (5)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01462630 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma

← Back to all trials